ReviewBlood2012
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
Review in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.Transplantation and cellular therapy · 2021Pooled it
- Pooled it
- Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study.Blood advances · 2020Trial
- Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019Trial
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.Journal of hematology & oncology · 2017Trial
- Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms.Bone marrow transplantation · 2016Trial
- Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Trial
- Trial
- A stem and progenitor cell-derived gene expression signature is prognostic for survival in myelofibrosis.Blood · 2026Article
- Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.Frontiers in oncology · 2026Review
- Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study.Future oncology (London, England) · 2025Observational
- Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib.Future oncology (London, England) · 2025Article
- Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era.Haematologica · 2024Article
- Myelofibrosis and allogeneic transplantation: critical points and challenges.Frontiers in oncology · 2024Review
- Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis.Bone marrow transplantation · 2023Article
- Reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for patients with myelofibrosis.Blood research · 2022Article
- Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States.The oncologist · 2022Article
- A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.Therapeutic advances in hematology · 2022Article
- Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?Hematology. American Society of Hematology. Education Program · 2021Review
- Using mitochondrial activity to select for potent human hematopoietic stem cells.Blood advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of symptoms associated with splenomegaly and MF-related constitutional symptoms, it is neither curative nor effective in reducing the risk of leukemic transformation. Presently, allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for MF. A significant risk of regimen-related toxicities, graft failure, and GVHD are major barriers to the success of HCT in MF. Because of significant HCT-associated morbidity and mortality, divergent opinions regarding its appropriate role in this clinical situation have emerged. In this review, the risk-benefit ratios of modern drug therapy compared with HCT in MF patients are analyzed. A risk-adapted approach individualized to each patient's biologic characteristics and comorbidities is described, which is currently warranted in determining optimal treatment strategies for patients with MF. Inclusion of JAK1/2 inhibitor therapy in future transplant conditioning regimens may provide an opportunity to overcome some of these barriers, resulting in greater success with HCT for MF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.